▲欲了解更多前沿技术在生物医药产业中的应用,请长按扫描上方二维码,即可访问“药明直播间”,观看相关话题的直播讨论与精彩回放
参考资料:
[1] iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients. Retrieved September 16, 2024, from https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-announces-clinically-meaningful-objective-response-rate
[2] Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signs of clinical activity in immune-resistant advanced cancers. Retrieved June 14, 2021, from https://www.iteostherapeutics.com/sites/default/files/2021-04/TIGIT%20poster%20AACR%202021_final%20210325.pdf
分享,点赞,在看,聚焦全球生物医药健康创新
▲欲了解更多前沿技术在生物医药产业中的应用,请长按扫描上方二维码,即可访问“药明直播间”,观看相关话题的直播讨论与精彩回放
参考资料:
[1] iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients. Retrieved September 16, 2024, from https://investors.iteostherapeutics.com/news-releases/news-release-details/iteos-announces-clinically-meaningful-objective-response-rate
[2] Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signs of clinical activity in immune-resistant advanced cancers. Retrieved June 14, 2021, from https://www.iteostherapeutics.com/sites/default/files/2021-04/TIGIT%20poster%20AACR%202021_final%20210325.pdf
分享,点赞,在看,聚焦全球生物医药健康创新